NVCT vs RLAY
NVCT: Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including breast, lung, prostate, and pancreatic cancers. RLAY: A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
Side-by-side fundamentals
| Metric | NVCT | RLAY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.29 | $19.27 | |
| Market cap as of 2026-07-23 | $608M | $4.2B | |
| PEG as of 2026-07-23 | -0.89 | n/a | |
| Net margin as of 2026-07-23 | n/a | -1859.7% | |
| Operating margin as of 2026-07-23 | n/a | -2023.7% | |
| ROE as of 2026-07-23 | -147.8% | -43.9% | RLAY higher |
| ROA as of 2026-07-23 | -90.8% | -40.1% | RLAY higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +39.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +123.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | -0.24 | 1.67 | |
| 1-year return as of 2026-07-22 close | +139.1% | +431.7% | RLAY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.